Over a 3-year period, 145 patients ineligible for myeloablative conditioning underwent reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (SCT) from an HLA-identical sibling in a prospective study. The median age was 54 years, 88 patients were male and 61 patients were beyond the early-intermediate phase of their disease. The 100-day probability of developing grade II-IV acute graft-versus-host disease (GVHD) was 34%, and the 1-year probability of developing chronic extensive GVHD was 41%. The 1-year probabilities of transplant-related mortality (TRM), overall (OS) and progression-free survival were 20, 60 and 52%, respectively. Multivariate analyses found a better OS in: (i) patients o60 years; and (ii) recipients of a first SCT; and a higher TRM in: (i) age 460 years, (ii) recipients of a prior autologous SCT, and (iii) an ECOG performance status 41. The 1-year TRM in patients with 0 or 1 and 42 of the above-mentioned adverse prognostic factors were 17 vs 53%, respectively (Po0.001). In summary, our study shows that elderly patients have a higher TRM following an RIC protocol. However, age by itself should not preclude these RIC transplants, since TRM appears to be unacceptably high only in the presence of additional adverse factors. Allogeneic stem cell transplantation (alloSCT) is a wellestablished treatment approach for numerous hematological malignancies. However, high-dose conditioning regimens designed to both control the malignancy and to prevent graft rejection are associated with a high mortality and a high incidence of acute and long-term side effects, especially in elderly or debilitated patients. A potential way to overcome this problem is by decreasing the intensity of chemotherapy and/or radiotherapy given prior to transplantation. Several groups of investigators have developed reduced-intensity conditioning (RIC) regimens that lead to successful engraftment in patients with hematological and nonhematological malignancies, without the extrahematologic toxicities of traditional myeloablative transplants.
Allogeneic stem cell transplantation (alloSCT) is a wellestablished treatment approach for numerous hematological malignancies. However, high-dose conditioning regimens designed to both control the malignancy and to prevent graft rejection are associated with a high mortality and a high incidence of acute and long-term side effects, especially in elderly or debilitated patients. A potential way to overcome this problem is by decreasing the intensity of chemotherapy and/or radiotherapy given prior to transplantation. Several groups of investigators have developed reduced-intensity conditioning (RIC) regimens that lead to successful engraftment in patients with hematological and nonhematological malignancies, without the extrahematologic toxicities of traditional myeloablative transplants. [1] [2] [3] [4] [5] [6] Based on numerous phase II trials, RIC are able to induce graft-versus-leukemia/tumor (GVL) effects with acceptable levels of extrahematologic toxicity. Thus, these attenuated regimens have been used mostly in older patients or patients with pre-existing organ dysfunction who would otherwise have a high risk of transplant-related mortality (TRM) after a myeloablative alloSCT. To date however, risk factors for TRM and their impact on overall survival (OS) after RIC transplants have not been described. We report here results of a prospective multicenter study of two RIC regimens (for myeloid and lymphoid malignancies) followed by allogeneic peripheral blood SCT (PBSCT) that is being conducted in several institutions in Spain, with special emphasis on pretransplant variables that influenced early TRM and OS.
Patients and methods

Patient selection
Eligibility criteria for entry into this RIC allogeneic PBSCT program included patients with a myeloid or lymphoid malignancy potentially treatable with an allogeneic transplant, who were 445 years old or who had received a prior autologous SCT. Patients gave written informed consent for inclusion in the protocol, which was approved by all local ethical review boards and the Spanish Drug Agency (protocol 99-0151). Between June 1999 and June 2002, 145 patients underwent an RIC PBSCT from an HLA-identical sibling in nine transplant centers in Spain.
Patient characteristics are shown in Table 1 . The median age was 54 years (range, 19-67 years), and there were 88 males and 57 females. Disease phase at transplant was categorized as early in 33 cases (acute leukemia or poor-risk myelodysplasia in first complete remission, untreated goodrisk myelodysplasia, first chronic-phase CML, lymphoid malignancy in first remission), intermediate in 28 patients (acute leukemia or myelodysplasia in second or higher complete remission, second chronic-phase CML, lymphoid malignancy in second or higher remission) and advanced in 84 cases (refractory or relapsed acute leukemia or myelodysplasia, blastic-phase CML, refractory or relapsed lymphoid malignancy and all second transplants). In all, 85 (59%) patients had received a prior autologous transplant a median of 14 months (range, 2-83) earlier. In total, 98 (67.5%) donor/recipient pairs were seropositive for cytomegalovirus (CMV) IgG pretransplant, in 13 (9%) donor was seronegative and recipient seropositive, in 11 (7.5%) the donor was seropositive and recipient seronegative, in nine (6%) donor/recipient pairs were seronegative and in 14 (10%) CMV status was missing. A sex difference occurred between donor and recipient in 68 cases (47%), with 47 males receiving a transplant from a female donor. All donors were HLA-identical siblings.
Conditioning regimens
Two RIC regimens were allowed. In all cases fludarabine 30 mg/m 2 intravenously (i.v.) for 5 consecutive days (À8 to À4 or À9 to À5) was used. In addition, patients received either melphalan at a dose of 70 mg/m 2 i.v. on days À3 and À2 (total 140 mg/m 2 ) (n ¼ 95) or busulfan 1 mg/kg Â 10 doses (days À6 to À4, total 10 mg/kg) (n ¼ 50), with phenytoin given as anticonvulsant prophylaxis. PBSC were infused on day 0. Graft-versus-host disease prophylaxis and supportive care
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A plus short-course methotrexate (MTX) in all cases, followed by folinic acid rescue at a dose of 10 mg i.v. every 6 h for four doses starting 24 h after each dose of MTX. 7 Infection prophylaxis consisted of norfloxacin or ciprofloxacin during the neutropenic period, fluconazole until hospital discharge and whenever steroids were used, standard-dose acyclovir (800 mg b.i.d. by mouth or 400 mg i.v. b.i.d.), and Bactrim 2 or 3 days per week from engraftment and until day þ 180. CMV antigenemia was monitored at least once weekly during the first 3 months post transplant and then as clinically indicated. Febrile neutropenia was managed by standard methods according to each institution's protocol.
Acute and chronic GVHD were graded by established criteria. 8 Grade II or greater acute GVHD was treated with prednisone or an equivalent at 2 mg/kg/day, with sub sequent tapering in responsive cases. Refractory GVHD was treated with antilymphocyte globulin or other salvage regimens.
Chimerism analysis
After transplant, serial samples of peripheral blood (PB) and bone marrow mononuclear cells were analyzed for degrees of donor-recipient chimerism using PCR of informative minisatellite regions following each center's standard methods. The sensitivity of all methods used was reported to be between 1 and 5% donor-derived cells by all participating centers, 9 and thus mixed chimerism is defined as 41% donor-derived cells in the sample analyzed, while the presence of 100% donor-derived DNA is considered complete donor chimerism.
Statistical analysis
The probability of OS was estimated from the time of transplantation using Kaplan-Meier product-limit estimate, while the probability of TRM was calculated using cumulative incidence estimates. For the end point of TRM, disease progression was regarded as a competing risk. Patients who died without disease progression were categorized as TRM, while patients alive without progression were censored at last follow-up and those who suffered disease progression were censored at progression. OS was calculated from transplant until death from any cause, and surviving patients were censored at last follow-up. The cumulative incidence and time to onset of acute GVHD and chronic GVHD were calculated in all patients who survived for at least 14 and 100 days after transplant, respectively.
Univariate analyses of the association of various clinical risk factors with the hazard of failure from TRM and OS were performed using univariate Cox's regression models. Factors examined are shown in Table 2 . Multivariate analyses were carried out with Cox's proportional-hazards regression, with inclusion of variables with a P-value o0.1 in the prior univariate testing. The assumption of proportional hazards over time was tested for all explanatory covariates using a time-dependent covariate. Two-sided P-values resulting from the regression models were derived using the Wald test, and no adjustments were made for multiple comparisons.
Results
Toxicity and TRM
Apart from transient nausea in some patients, the preparative regimens were generally well tolerated. Six patients (4%) died early before engraftment, three of them due to toxicity attributable to the conditioning regimen, one due to disease progression and two patients from infection.
The 1-year cumulative incidence of TRM was 20% (95% CI, 15-29%). Univariate Cox's regression analyses of the risk of TRM according to various pretransplant clinical variables found a higher risk of TRM in patients X60 years of age (n ¼ 36) vs those aged o60 years (n ¼ 109) (hazard ratio (HR) 2.03 (95% CI, 1.01-4.06), P ¼ 0.04), in those who had received a previous autologous SCT (n ¼ 60) vs patients who had not received a previous transplant (n ¼ 85) (HR 1.95 (95% CI, 0.99-3.87), P ¼ 0.05) and in those with an ECOG performance status (PS) of 2 or 3 (n ¼ 12) (HR 2.9 (95% CI, 1.2-7), P ¼ 0.02). Other variables analyzed did not influence the TRM (see Table 2 ). Multivariate Cox's regression analysis of the risk of TRM found a higher risk of TRM in patients with the same clinical variables: age X60 years (P ¼ 0.038), previous transplant (P ¼ 0.021) and ECOG PS 2 or 3 at transplant (P ¼ 0.031) (Figure 1 ). Figure 2 shows the TRM according to the number of adverse features (0-1 or 2-3) at transplant.
The 180-day cumulative incidence of developing CMV infection was 21% (n ¼ 30 patients), but only four patients developed CMV disease, for an incidence of 2%. Two patients had died from CMV disease at last follow-up.
Hematologic recovery and chimerism
The infused allograft contained a median of 5.34 Â 10 6 CD34 þ cells/kg (range, 1.9-15.6). Hematologic recovery was prompt in all but the six early deaths. Neutrophils decreased to o0.5 Â 10 9 /l in all cases and recovered at a median of day þ 15 (range, þ 6 to þ 32), and the median time to reach a stable platelet count 420 Â 10 9 /l was day þ 11 (range, þ 0 to þ 42). On days þ 21 to þ 28, 84/104 (81%) patients tested showed a pattern of complete donor chimerism in BM and 86/104 (83%) patients in PB. The proportion of patients with complete donor chimerism on days þ 90 to þ 100 were 68/86 (80%) in BM and 86/104 (83%) in PB, at 6 months 36/44 (82%) in BM and 46/52 (88%) in PB and at 1 year 35/39 (90%) in BM and 35/36 (97%) in PB.
Acute and chronic GVHD
Acute GVHD grade XII occurred in 50 patients, for a 100-day cumulative incidence of 34% (95% CI, 28-43%). The median day of onset was þ 29 (range, þ 4 to þ 97). Out of the 50 patients, 18 developed acute GVHD grade III-IV. The 100-day cumulative incidence of acute GVHD grade II-IV in the 109 patients o60 years of age was 33% (95% CI, 29-37%), and in the 36 patients X60 years of age it was 33% (95% CI, 25-41%). Of 106 evaluable patients, 79 developed chronic GVHD, which was extensive in 43 cases. The 1-year probability of developing chronic extensive GVHD was 41% (95% CI, 33-52%). The 1-year cumulative incidence of developing chronic extensive GVHD in patients o60 years was 39% (95% CI, 34-44%), and in patients X60 years of age it was 47% (95% CI, 37-57%), without statistical significance.
Responses and outcome
As of October 2002, 84 patients are alive, with a median follow-up of 19 months (range, 3-51); 12 patient are alive after disease progression, while 72 are alive in complete remission (n ¼ 61) or in partial remission/stable disease (n ¼ 11). The 1-year OS and progressionfree survival were 60% (95% CI, 52-62%) and 52% (95% CI, 44-60%), respectively. Univariate Cox's regression analyses of OS according to various Table 2 ). Multivariate Cox's regression analysis of OS found only a better survival in patients o60 years old (P ¼ 0.013) and recipients of a first SCT (P ¼ 0.014) (Figure 3 ).
Discussion
Advances in hematopoietic SCT have reduced the toxicity of allogeneic and autologous transplantation. Changes in transplantation practices, including the use of cytokines, PB stem cells rather than harvested bone marrow, less toxic conditioning regimens and multiple advances in supportive care have helped to reduce the toxicity and TRM after allogeneic SCT. These changes in transplantation have allowed patients of more advanced age to be considered on an individual basis for transplantation. [10] [11] [12] [13] [14] In recent years, the use of nonmyeloablative or RIC conditioning regimens for allografting have been shown to lead to engraftment of donor stem cells without the toxicities of traditional myeloablative transplants. [1] [2] [3] [4] [5] [6] [7] Many initial reports of RIC allogeneic transplantation included patients who were ineligible for conventional SCT because of older age or organ dysfunction. In fact, the mean patient age in the nonmyeloablative protocols is often in the mid-50s. Regimen-related toxicities were mild and showed the feasibility of this procedure. However, no prospective studies have analyzed the impact of age on the outcome of RIC allografts. Another criterion for including patients in our and other RIC programs is having failed a prior autologous SCT, 15, 16 since second conventional allografts in adults carry a very high risk of TRM. Our current study included the first 145 patients who were enrolled in our national prospective RIC program over a 3-year period. Our results indicate that some traditional variables still have an impact on patient outcome after an RIC allograft. Thus, age X60 years, poor PS and having received a prior SCT all lead to very high rates of TRM (450%) after conventional myeloablative transplantation. Two of these variables also decreased OS (advanced age and prior SCT), after an RIC transplant. Since RIC regimens differ in many ways, such as the relative intensity of alkylators used and the use of antilymphocyte antibodies, our results may not apply to other published regimens. [1] [2] [3] [4] [5] [6] [7] Our RIC protocols have been shown to lead to a state of complete donor chimerism in most patients, without the need for donor lymphocyte infusions or early withdrawal of immunosuppression. 9 In consequence, GVHD (acute and/ or chronic) occurs spontaneously in most patients. 7, 9, 17 We and others have observed a strong association between GVHD and decreased risk of disease progression in both myeloid and lymphoid malignancies. 9, [18] [19] [20] [21] The occurrence of moderate to severe GVHD, however, also increases the risk of developing life-threatening infections. [21] [22] [23] [24] Elderly or debilitated patients tolerate GVHD and its treatment poorly, thus explaining our risk factors for TRM and OS. Thus, the same criteria that are used for selecting patients for an RIC transplant also increase the TRM and reduce survival. We should emphasize that although advanced age and second transplants increased the risk of TRM, this risk is very high (430%) only in patients with more than one adverse pretransplant characteristic (Figures 1  and 2 ). Another variable that may also increase the risk of severe GVHD and TRM after an RIC transplant is the use of alternative donors (mismatched related donors, volunteer unrelated donors with variable antigen/allele mismatches), 25, 26 but all our patients received an SCT from an HLA-identical sibling.
In summary, our study shows that elderly patients have a higher TRM following an RIC protocol. However, age by itself should not preclude these RIC transplants, since TRM appears to be unacceptably high only in the presence of additional adverse factors.
